Breaking News, Collaborations & Alliances

ProBioGen, Granite Bio Enter Development and Manufacturing Partnership

Closure of Master Services Agreement to support development of Granite’s mAb pipeline.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Granite Bio, a Swiss biotech company built through Versant Venture’s discovery engine Ridgeline Discovery, and ProBioGen, a contract development and manufacturing organization (CDMO), have closed a Master Services Agreement to support the development of Granite Bio’s mAb pipeline. Granite Bio’s lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. By using the DirectedLuck (https://www.probiogen.de/directedluck-transposase-...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters